Table 2 Meta-analysis results for included studies of the relationship between risk factors and mortality in SLE-associated DAH patients
Variables | No. of studies | Number of enrolled episodes | Effects model | I2 (%) | OR/SMD (95%CI) | P values | Relationship | Publication bias (P value of Begg’s test) |
|---|---|---|---|---|---|---|---|---|
Demographic and clinical characteristics | ||||||||
Age | 7 | 243 | Fixed | 0.0% | 0.35 (0.08, 0.61) | 0.010 | Increased risks | None (1.000) |
Female | 4 | 189 | Fixed | 42.6% | 0.69 (0.31, 1.54) | 0.369 | No association | None (0.734) |
Disease duration | 6 | 226 | Fixed | 0.0% | 0.28 (0.01, 0.55) | 0.042 | Increased risks | None (0.260) |
Lupus nephritis | 3 | 140 | Random | 58.4% | 5.45 (0.52, 56.95) | 0.160 | No association | None (0.296) |
NPSLE | 3 | 124 | Fixed | 42.2% | 0.96 (0.43, 2.15) | 0.920 | No association | None (1.000) |
Laboratory data and disease activity | ||||||||
Platelet | 6 | 219 | Random | 69.1% | − 0.29 (− 0.86, 0.29) | 0.328 | No association | None (0.260) |
Drop of hemoglobin | 5 | 202 | Random | 57.5% | 0.34 (− 0.17, 0.85) | 0.190 | No association | None (0.806) |
C3 | 3 | 132 | Random | 77.0% | 0.48 (− 0.51, 1.46) | 0.340 | No association | None (1.000) |
SLEDAI | 6 | 186 | Random | 76.9% | 0.24 (− 0.52, 0.99) | 0.540 | No association | None (1.000) |
Comorbidity and treatment | ||||||||
Infection | 6 | 223 | Fixed | 37.5% | 2.77 (1.55, 4.95) | 0.001 | Increased risks | None (0.260) |
CTX treatment | 6 | 224 | Random | 75.5% | 0.74 (0.16, 3.41) | 0.700 | No association | None (1.000) |
IVIG treatment | 3 | 175 | Random | 61.2% | 1.28 (0.24, 6.87) | 0.780 | No association | None (0.296) |
Plasmapheresis | 5 | 167 | Fixed | 14.6% | 1.96 (1.04, 3.70) | 0.038 | Increased risks | None (0.806) |
Mechanical ventilation | 8 | 262 | Fixed | 23.3% | 6.11 (3.27, 11.39) | < 0.0001 | Increased risks | None (1.000) |